The Antibiotic Resistance Profile of Pseudomonas Aeruginosa in a Tertiary Medical Center from Malaysia
DOI:
https://doi.org/10.3329/jom.v23i1.57938Keywords:
Carbapenem, multidrug resistance, piperacillin-tazobactam, polymyxin B, Pseudomonas aeruginosaAbstract
Background: Pseudomonas aeruginosa is a notorious gram-negative bacterium that has become a globalpublic health concern owing to the emergence of multi- and pandrug-resistant strains. This study sought todetermine the antibiotic susceptibility profile of P. aeruginosa in a tertiary medical center from Malaysia.
Materials and Methods: Each isolate’s identity was confirmed using the VITEK 2 GN kit, and subjectedto antibiotic susceptibility testing using the VITEK 2 AST-N374 card (for testing against piperacillintazobactam,ceftazidime, cefepime, imipenem, meropenem, amikacin, gentamicin and ciprofloxacin) andEtest strips (for testing against doripenem and polymyxin B). Isolates which were not susceptible to >1carbapenem were tested for carbapenemase production using the modified carbapenem inactivationMethod (mCIM).
Results: Out of 102 isolates studied, 64 (62.7%) were fully susceptible to all the antibiotics tested.Twenty-six (25.5%) were resistant to >1 antibiotic from >2 antibiotic classes, and 21 (20.6%) wereresistant to >1 antibiotic from >3 classes. Susceptibility was highest with polymyxin B (100%) and lowestwith piperacillin-tazobactam (64.7%). Carbapenem susceptibility was between 78.4% to 81.4%. Out of 22isolates which were not susceptible to >1 carbapenem, 18 (81.8%) were not susceptible to all threecarbapenems.
Conclusion: More than half of our P. aeruginosa isolates were fully susceptible to all the anti-pseudomonalantibiotics tested. Multidrug-resistant strains accounted for between 20% to 25% of all our P. aeruginosaisolates. Through mCIM testing, carbapenemase production did not appear to be the dominant resistancemechanism.
J MEDICINE 2022; 23: 54-60
Downloads
54
83
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).